Colorectal Cancer Patients Enrolled in Trial of NeoPharm Drug
Posted on: Wednesday, 31 May 2006, 12:00 CDT
NeoPharm has announced that patient enrollment has begun in a multi-center phase II clinical trial of the company's investigative drug LE-SN38 in the treatment of patients with metastatic colorectal cancer.
The trial is being conducted by Cancer and Leukemia Group B (CALGB), an oncology clinical research group sponsored by the National Cancer Institute (NCI).
LE-SN38 is NeoPharm's NeoLipid liposomal formulation of SN-38, the active metabolite of irinotecan (Camptosar), a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer.
"Our LE-SN38 drug candidate, as well as the underlying NeoLipid drug delivery platform are an important part of our oncology portfolio," said Guillermo Herrera, NeoPharm's president and CEO. "We are pleased to be moving LE-SN38 into phase II testing with CALGB, one of the premiere oncology clinical research groups, in the hope of eventually providing colorectal cancer patients with a new and potentially less toxic treatment option."
The phase II trial will seek to enroll up to 54 patients. The primary endpoint of the trial is overall tumor response rate following treatment with LE-SN38 as a second-line treatment in patients with metastatic colorectal cancer. Other endpoints include determining the safety profile of LE-SN38 in this patient population, as well as the progression-free survival and overall survival for the patients treated.
Source: Datamonitor
Related Articles
- Alfacell's ONCONASE(R) Shows Potential As Radiation Sensitizer for Lung Cancer Treatment
- Alfacell's ONCONASE(R) Shows Promise As Radiation Sensitizer for Lung Cancer Treatment
- Light Sciences Oncology Initiates Phase III Trial of Its Light Infusion Therapy (Litx(TM)) in Patients With Metastatic Colorectal Cancer
- Study Shows Advantages of Complete Phase Ib Trial Over Separate Phase I Trials
- The Burgeoning Use of Surrogate End Points Creates a Significant Need to Identify New Biomarkers - Challenges in Oncology Clinical Trial Design
- New Brain Cancer Treatment is Evaluated
- BSD Medical Presents Cutting-Edge Cancer Treatment Systems at New York Oncology Congress
- Phase II Clinical Trial of NeoPharm's LE-SN38 Initiated By NCI CALGB in Patients With Metastatic Colorectal Cancer; First Patients Treated
- Breast Cancer Treatment Touted ; Drug Useful Against Early-Stage Disease
- Specialists Welcome New Colorectal Cancer Treatment
 |
 |
User Comments (0)
RSS Feeds